CN Patent

CN101115726A — 作为cb1拮抗剂的取代哌嗪

Assigned to Merck Sharp and Dohme LLC · Expires 2008-01-30 · 18y expired

What this patent protects

式(I)化合物或其可药用盐、溶剂合物或酯，可用于治疗由CB 1 受体介导的疾病或病症，如代谢综合症和肥胖症、神经发炎疾病、认知疾病和精神病、成瘾(例如戒烟)、肠胃疾病及心血管病症。

USPTO Abstract

式(I)化合物或其可药用盐、溶剂合物或酯，可用于治疗由CB 1 受体介导的疾病或病症，如代谢综合症和肥胖症、神经发炎疾病、认知疾病和精神病、成瘾(例如戒烟)、肠胃疾病及心血管病症。

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

Patent Metadata

Patent number: CN101115726A
Jurisdiction: CN
Classification: —
Expires: 2008-01-30
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.